Secukinumab for hidradenitis suppurativa

Secukinumab is in clinical development for adult patients with moderate to severe hidradenitis suppurativa (HS). HS is a painful, long term skin condition that causes abscesses and scarring on the skin. The exact cause of HS is unknown, but it occurs near hair follicles where there are sweat glands, usually around the groin, bottom, breasts and armpits. Mild to moderate HS has been successfully treated with oral antibiotics, topical therapy, and lifestyle modifications. However, moderate to severe HS is known to be unresponsive to normal treatments. Surgery is an option for severe HS, but it can cause problems for the patient and the disease may still return. There is a need for safe and effective treatments for patients with moderate to severe HS.